A New Era of Cancer Treatment

We are developing a robust clinical pipeline of chimeric antigen receptor (CAR) and T cell receptor (TCR) products.

Our most advanced candidate, KTE-C19, is currently in a pivotal trial for the treatment of refractory, aggressive non-Hodgkin Lymphoma (NHL), and we estimate interim data to be available in 2016.  Additional indications in NHL and leukemia are being pursued with KTE-C19.

We also expect to advance our first TCR product candidate to a company-sponsored clinical trial in 2016.

Learn more about our ongoing clinical trials at www.clinicaltrials.gov.

Kite Pharma Expanded Access Policy

Treating physicians may request information about Expanded Access for a Kite Pharma therapy by contacting Kite Medical Information at 1-844-454-KITE

Kite will evaluate these requests individually. Kite may provide physician requested Expanded Access for a Kite therapy for patients with no other available therapies and for patients who are not eligible to participate in a current Kite clinical trial. Kite will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.

Kite does not currently have any active Expanded Access protocols but we do have Clinical Trials open. These can be found on ClinicalTrials.gov.

Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.